Fortress Biotech

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Nov.  25, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that it has priced an underwritten public offering of 262,500 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of approximately $5.3 million. In addition, Fortress has granted the underwriters a 45-day option to purchase up to 39,375 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 29, 2019, subject to customary closing conditions.

Fortress Biotech  Announces Pricing of Series A Preferred Stock Offering

NEW YORK, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced it ranked number 10 in Deloitte’s 2019 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress’ 8,463 percent revenue growth based on the increase in net product sales from 2015 to 2018 secured its spot in the ranking.

Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™

NEW YORK, Oct.  24, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview at the 5th Annual Dawson James Small Cap Growth Conference on Tuesday, October 29, 2019, at 10:55 a.m. EDT at the Wyndham Grand Hotel in Jupiter, Florida. Dr. Rosenwald will also participate in the “New Paradigms in Biotechnology Business Development: A Fireside Chat with Two Successful Entrepreneurs” panel on Tuesday, October 29, 2019, at 8:30 a.m. EDT.

Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference

NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences.

Fortress Biotech to Present at October 2019 Investor Conferences

NEW YORK, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that the company will present at two investor conferences in September 2019.

Fortress Biotech to Present at September 2019 Investor Conferences

NEW YORK, Aug.  19, 2019  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced that Kevin L. Lorenz, J.D., has been appointed to its Board of Directors. Mr. Lorenz, Chief Investment Officer, Senior Vice President, Treasury & Private Investments at the Katz Group, is an accomplished executive with over 25 years of experience guiding and implementing investment strategy across public and private companies. The Katz Group, which is one of Canada’s leading privately-owned enterprises, owns 4,675,000 common shares of Fortress stock, or 6.9% of the Company’s issued and outstanding common stock.

Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D.

As of late, it has definitely been a great time to be an investor Fortress Biotech.

Will Fortress Biotech to Surge Higher?

Mustang Bio

Mustang Bio, Inc. soared last Thursday after the very successful results of its gene therapy.

Mustang Set To Become A Mini-Sarepta On Bubble Boy Miracle Cure; Fortress Along For The Ride

Fortress Biotech Inc 9.375 % Cum Conv Perp Red Pfd Registered Shs Series A

Fortress Biotech continues to make strides since bottoming out in December.

Plenty Of Further Upside In Fortress Biotech

News for Fortress Biotech Stock (FBIO)